Insider · CIK 0002128919
Mads Nikolaj Behrndt-Eriksen
Files at COAG (Hemab Therapeutics Holdings, Inc.). First filing -, latest -.
Mads Nikolaj Behrndt-Eriksen files SEC Form 4 as officer at COAG (Hemab Therapeutics Holdings, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mads Nikolaj Behrndt-Eriksen has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 29, 2026 | COAG Hemab Therapeutics Holdings, Inc. | AGrant or award Warrants (Right to Buy)derivative | +195,206 | $0.00 | $0 | 195,206 | May 4, 2026 |
| Apr 30, 2026 | COAG Hemab Therapeutics Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +49,016 | $0.00 | $0 | 49,016 | May 4, 2026 |
Questions about Mads Nikolaj Behrndt-Eriksen
Answered from the filings on this page, as of the latest one.
Is Mads Nikolaj Behrndt-Eriksen buying or selling?
Mads Nikolaj Behrndt-Eriksen has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mads Nikolaj Behrndt-Eriksen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mads Nikolaj Behrndt-Eriksen has 0.
Where does Mads Nikolaj Behrndt-Eriksen file Form 4?
Mads Nikolaj Behrndt-Eriksen has filed Form 4 at COAG (Hemab Therapeutics Holdings, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.